Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02235077 · ClinicalTrials.gov registry record · Phase 2

Study of High-dose Spironolactone vs. Placebo Therapy in Acute Heart Failure

A Phase 2 study, sponsored by Duke University.

Completed
Registry status
Phase 2
Development phase
360
Enrollment target

NCT02235077: Completed Phase 2 study, sponsored by Duke University.

NCT02235077 is a Phase 2 study that has completed, run by Duke University. The registered enrollment target is 360 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (171% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02235077, a Phase 2 study, has completed, sponsored by Duke University.

COMPLETED
Registry status
Phase 2
Development phase
360 participants
Enrollment target

Study Summary

The primary objective of this study is to test the hypothesis that high-dose spironolactone will lead to greater proportional reduction in NT-proBNP levels from randomization to 96 hours over standard of care.

Primary Outcome

The Core Laboratory at Vermont will determine NT-proBNP levels for calculation of the endpoint from samples obtained at randomization and 96 hours respectively. NT-proBNP was converted to log scale.

Interventions

  • DRUG Placebo
  • DRUG Spironolactone

Trial Details

FieldValue
Enrollment Target 360 participants
Start Date 2014-12-30
Est. Completion 2016-06-06
Phase Phase 2
Duke University

1,725 total trials

What the finished NCT02235077 record still lists

NCT02235077 is an interventional study that assigns participants to a tested intervention. The registered 360 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (171% higher).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT02235077 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02235077 about?

NCT02235077 is a clinical study titled "Study of High-dose Spironolactone vs. Placebo Therapy in Acute Heart Failure". The primary objective of this study is to test the hypothesis that high-dose spironolactone will lead to greater proportional reduction in NT-proBNP levels from randomization to 96 hours over standard of care.

What is the current status of trial NCT02235077?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 360 participants. The study started on 2014-12-30. Estimated completion is 2016-06-06.

What interventions are being tested in trial NCT02235077?

The interventions under investigation include: Placebo (DRUG), Spironolactone (DRUG).

Who is sponsoring clinical trial NCT02235077?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02235077's enrollment target sits among peer trials

360 123rd of 2000 higher than 1,874 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02747836 · 360 participants

    Ultrasound Analysis of Human Carpal Tunnel System

  • NCT04089046 · 360 participants · NA

    Telemedicine Enhanced Asthma Management - Uniting Providers for Teens (TEAM-UP for Teens)

  • NCT04130503 · 360 participants · NA

    The Recovery in Stroke Using PAP Study

  • NCT04160000 · 360 participants · Phase 4

    Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02235077, the US trial registry maintained by the National Library of Medicine. NCT02235077 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.